Symptoms and General Pathology

All Conditions

Heart and Blood Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Recurrence

Thrombosis

Venous Thrombosis

Hemorrhage

Pulmonary Embolism

Embolism

Thromboembolism

Venous Thromboembolism

Embolism and Thrombosis

Vascular Diseases

Lung Diseases

Respiratory Tract Diseases

Anticoagulants

All Drugs and Chemicals

Fibrinolytic Agents

Heparin, Low-Molecular-Weight

Tinzaparin

Dalteparin

Heparin

Calcium heparin

Abelacimab intravenous administration followed by monthly administration of the same dose subcutaneously

Dalteparin administered subcutaneously daily

Abelacimab

Dalteparin 200 IU/kg/day followed by 150 IU/kg/day

Nancy Widener

Deb Freedholm

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. Patients with intact GI and GU cancer have increased bleeding risk with oral direct anticoagulants (DOACs), Guidelines advice caution with those DOACs or state preference for low molecular weight heparin (LMWH) in this population. The ANT-008 study will compare treatment with abelacimab monthly administration to LMWH daily subcutaneous (sc) administration over 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

Itreas

Anthos Therapeutics, Inc.

Anti-Infective Agents

Amino Acids

Apixaban

Factor Xa Inhibitors

Antithrombins

Antithrombin III

Protease Inhibitors

Serine Proteinase Inhibitors

HIV Protease Inhibitors

Enzyme Inhibitors

Serine

Nancy Weidner

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Cancer associated thrombosis (CAT) is a severe medical condition which is characterized by high incidence of Venous thromboembolism (VTE) recurrence and high risk for bleeding. The two most common treatments today are low molecular weight heparin (LMWH) and direct anticoagulants (DOACs), in which each has limitations. DOACs are administered orally and are seen as a more convenient alternative though associated with bleeding risk; further, some cancer patients have difficulty swallowing or develop vomiting which leads to unpredictable pharmacodynamic effects with oral therapy. The ANT-007 study will compare treatment with abelacimab monthly administration to apixaban twice daily administration over a 6-month treatment. The study outcomes include VTE recurrence, bleeding event and treatment discontinuation at 6 months

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE	NCT05171075	Venous Thromboe... Deep Venous Thr... Pulmonary Embol...	Abelacimab Dalteparin	18 Years -	Anthos Therapeutics, Inc.
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE	NCT05171049	Venous Thromboe... Deep Venous Thr... Pulmonary Embol...	Abelacimab Apixaban	18 Years -	Anthos Therapeutics, Inc.
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE	NCT05171049	Venous Thromboe... Deep Venous Thr... Pulmonary Embol...	Abelacimab Apixaban	18 Years -	Anthos Therapeutics, Inc.
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE	NCT05171075	Venous Thromboe... Deep Venous Thr... Pulmonary Embol...	Abelacimab Dalteparin	18 Years -	Anthos Therapeutics, Inc.

Spots Global Cancer Trial Database for vte recurrence rate